Developing IP Strategies for Crystalline Forms 2010

Maximising Crystalline Form Patent Wealth through Effective Patenting, Litigation and Lifecycle Extension
In less than 24 months, 26 blockbuster medicines, worth over $69 billion or thrice the size of the domestic industry are going off-patent April 27, 2010, Joe C Mathew, Business Standard

As an increasing number of blockbuster patents expire and R&D piplelines shrink, it is becoming increasingly important to have a successful application and litigation strategy to protect and maximise the revenue from existing patents. A substantial proportion of pharmaceutical products are crystalline forms which, due to the intricacies of obviousness and novelty, are notoriously difficult to patent and litigate. In light of this, Pharma IQ s Developing IP Strategies for Crystalline Forms 2010 conference will bring together leading professionals working within in house counsel, patent offices, law firms and Judiciary to explore the challenges, trends and successful approaches employed and in turn, help you to maximise return from crystalline patents.